Avibactam is a β-lactamase inhibitor that is in clinical development, combined with β-lactam
partners, for the treatment of bacterial infections comprising Gram-negative organisms …

In gram-negative bacteria, beta-lactamases are the most important mechanism of resistance
to beta-lactam antibiotics. Currently, the beta-lactamases receiving the most attention are the …

The β-lactams have been among the most successful classes of antibacterial agents for the
past half century. However, a disturbing increase in resistance to β-lactams has been noted …

Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline,
or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases …

Introduction: The burden of antimicrobial resistance among Gram-negative bacteria is
increasing and growing into a major threat of public health. Treatment options for …

The use of successive generations of β-lactams has selected successive generations of β-
lactamases including CTX-M ESBLs, AmpC β-lactamases, and KPC carbapenamases in …

Although there is no consensus of the precise definition of ESBL, three kinds of ESBL
definitions have been proposed. First, the classical definition includes variants derived from …

Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic
boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam …

β-lactam antibiotics are one of the most widely used and diverse classes of antimicrobial
agents for treating both Gram-negative and Gram-positive bacterial infections. The β-lactam …

As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-
resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa …